Detecting lung cancer early saves lives.1
Breakthrough Technology
FirstLook uses a unique fragmentomics technology that analyzes DNA fragment patterns to help screen for lung cancer.2,5
Easily Accessible
FirstLook makes lung cancer screening accessible to all eligible adults by keeping the process simple.
Simple & Efficient
The FirstLook blood test can be incorporated into routine appointments, making it easier for more adults to start lung cancer screening.
15.1 million Americans are at an elevated risk for lung cancer and are screen-eligible, but most are not getting the necessary screening to detect it early before signs or symptoms appear.3
Whether it’s due to inaccessible screening methods or lack of awareness, the vast majority of eligible adults aren’t getting the nationally recommended low-dose CT (LDCT) screening.4
The FirstLook test has a negative predictive value* of 99.8%.5
The FirstLook blood test offers a convenient and accessible way to enhance lung cancer screening and early lung cancer detection.
*The negative predictive value represents the percentage of individuals with a Not Elevated result who do not have low-dose CT detectable lung cancer. The clinical validity of FirstLook Lung was established by a prospective, case-controlled study in a population of screen-eligible patients.2
FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.
The FirstLook Lung test is a laboratory-developed test. It was developed and its performance characteristics determined by DELFI Diagnostics. It has not been cleared or approved by the FDA. The laboratory is regulated under the Clinical Laboratory Improvement Act (CLIA) as qualified to perform high complexity clinical tests. This test is used for clinical purposes. It should not be regarded as investigational or for research.
1. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 365(5), 395-409. 2. Mazzone PJ, et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024 Jun 3. doi: 10.1158/2159-8290.CD-24-0519. Epub ahead of print. PMID: 38829053. 3. Meza, R., Jeon, J., Toumazis, I., Ten Haaf, K., Cao, P., Bastani, M., Han, S. S., Blom, E. F., Jonas, D. E., Feuer, E. J., Plevritis, S. K., de Koning, H. J., & Kong, C. Y. (2021). Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA, 325(10), 988–997. 4. Wang GX, Baggett TP, Pandharipande PV, Park ER, Percac-Lima S, Shepard JO, Fintelmann FJ, Flores EJ. Barriers to Lung Cancer Screening Engagement from the Patient and Provider Perspective. (2019). Radiology, 290(2), 278-287. 5. Unpublished data on file.
